Novel Use of Nivolumab and Ipilimumab in Pediatric Patients with Relapse or Refractory INI1-Negative Cancers (Phase II)

Pediatric Rare Cancer
Suzanne Forrest, MD
Dana-Farber Cancer Institute

Summary:

In this trial, Dr. Forrest and team are using a dual immunotherapy approach to treat pediatric patients with recurrent or relapsed INI1-negative cancers. This group of cancers is both rare and aggressive, resulting in a poor prognosis for these children. Currently, there is no standard of care. If the study is successful, it will establish the proposed dual immunotherapy approach as the standard of care for children with recurrent or relapsed INI1-negative cancers.